Henlius collaboration expands Sandoz biosimilar pipeline
KEY STEPOn August 17, 2026, Sandoz announced a development, manufacturing and commercialization collaboration with Shanghai Henlius Biotech covering up to 10 biosimilar assets. The initial agreement increased the disclosed Sandoz biosimilar pipeline to 39 assets, with potential to reach up to 46.
Roadmap reference